Galunisertib (LY2157299) is a small molecular experimental cancer drug previously in development by Eli Lilly.

It is a TGF-b inhibitor.

[1] Development of galunisertib by Eli Lilly was discontinued in January 2020.

[2] Galunisertib was investigated in a phase II trial for treatment of hepatocellular carcinoma.

[3] Pre-clinically, combination of galunisertib with PD-L1 blockade resulted in improved tumor growth inhibition.